B7H3/PDL1 Bispecific Antibody Cancer Therapeutic
Summary
The USPTO published patent application US20260092116A1 by DARTSBIO Pharmaceuticals Ltd. covering a B7H3/PDL1 bispecific antibody for cancer treatment. The invention comprises a monoclonal antibody targeting PDL1 linked to nano-antibodies targeting B7H3, designed to relieve T-cell inhibition while targeting tumor cells. The application was filed October 13, 2022, with six inventors.
What changed
DARTSBIO Pharmaceuticals Ltd. filed USPTO Application US20260092116A1 for a bispecific antibody combining PDL1 monoclonal antibody units with B7H3 nano-antibody units using linker peptides. The invention targets both B7H3 and PDL1 simultaneously to overcome tumor immune evasion, demonstrating superior anti-tumor activity compared to combination monoclonal antibody therapies. Application No. 19120240 was published April 2, 2026.
Patent application publication does not impose compliance deadlines on industry. Pharmaceutical companies developing bispecific antibodies or immune-oncology therapeutics should monitor this application for potential freedom-to-operate considerations. No action is required at this stage; stakeholders may review the claims when the patent proceeds through examination.
Archived snapshot
Apr 3, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
B7H3/PDL1 BISPECIFIC ANTIBODY, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AND USE THEREOF
Application US20260092116A1 Kind: A1 Apr 02, 2026
Assignee
DARTSBIO PHARMACEUTICALS LTD.
Inventors
Yili CHEN, Chunhe WANG, Huanhuan LI, Guojian LIU, Jie TAN, Lei TANG
Abstract
The present invention relates to a B7H3/PDL1 bispecific antibody, and a pharmaceutical composition comprising same and a use thereof. The bispecific antibody can bind to B7H3 and PDL1 in a targeted manner, and comprises: a monoclonal antibody unit, targeting PDL1 and comprising two heavy chains and two light chains; and a nano-antibody unit, targeting B7H3 and comprising two identical nano-antibodies, wherein the C-terminuses of the two nano-antibodies are respectively linked to the C-terminuses of the Fc fragments of the two heavy chains of the monoclonal antibody unit by means of a linker peptide. The bispecific antibody of the present invention can bind to both B7H3 and PDL1, can relieve inhibition of T cells by PDL1 while targeting tumor cells, and shows anti-tumor activity superior to that of a drug combination using a monoclonal antibody.
CPC Classifications
C07K 16/2827 A61P 35/00 A61K 2039/505 C07K 2317/31 C07K 2317/732 C07K 2317/92
Filing Date
2022-10-13
Application No.
19120240
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.